SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules

Fecha de publicación

2023-02-16T11:46:04Z

2023-02-16T11:46:04Z

2022-11-22

2023-02-16T11:46:04Z

Resumen

Antiviral agents are needed for the treatment of SARS-CoV-2 infections and to control other coronavirus outbreaks that may occur in the future. Here we report the identification and characterization of RNA-binding compounds that inhibit SARS-CoV-2 replication. The compounds were detected by screening a small library of antiviral compounds previously shown to bind HIV-1 or HCV RNA elements with a live-virus cellular assay detecting inhibition of SARSCoV-2 replication. These experiments allowed detection of eight compounds with promising antiSARS-CoV-2 activity in the sub-micromolar to micromolar range and wide selectivity indexes. Examination of the mechanism of action of three selected hit compounds excluded action on the entry or egress stages of the virus replication cycle and confirmed recognition by two of the molecules of conserved RNA elements of the SARS-CoV-2 genome, including the highly conserved S2m hairpin located in the 3'-untranslated region of the virus. While further studies are needed to clarify the mechanism of action responsible for antiviral activity, these results facilitate the discovery of RNA-targeted antivirals and provide new chemical scaffolds for developing therapeutic agents against coronaviruses.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Materias y palabras clave

COVID-19; RNA; COVID-19; RNA

Publicado por

MDPI

Documentos relacionados

Reproducció del document publicat a: https://doi.org/10.3390/ph15121448

Pharmaceuticals, 2022, vol. 15, p. 1448

https://doi.org/10.3390/ph15121448

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by (c) Simba Lahuasi, Alvaro et al., 2022

https://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)